Significance of the preoperative regional maximal removal rate of technetium-99m-galactosyl human serum albumin in the future remnant liver: a sequential study of regional maximal removal rate of technetium-99m-galactosyl human serum albumin in the whole liver.


Journal

Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017

Informations de publication

Date de publication:
Feb 2019
Historique:
entrez: 17 1 2019
pubmed: 17 1 2019
medline: 5 2 2019
Statut: ppublish

Résumé

The relationship between posthepatectomy complications and liver functional parameters was preliminary reported in a pilot study. The present study sequentially evaluated the clinical significance of maximal removal rate of technetium-99m-galactosyl human serum albumin (GSARmax) in the future remnant liver (rGSARmax) in patients to predict posthepatectomy complications. Between 2010 and August 2017, GSARmax, rGSARmax, their difference (Dif), and the rGSARmax to GSARmax ratio were examined in 247 additional patients who underwent hepatectomy for liver and biliary diseases. Hepatectomy-related postoperative complications (i.e. long-term ascites, intra-abdominal infection, and hepatic failure) occurred in 73 (29.6%) patients. The median and mean preoperative GSARmax values were 0.477 and 0.498±0.166 mg/min, respectively; rGSARmax values were 0.341 and 0.366±0.145 mg/min, respectively; Dif values were 0.105 and 0.132±0.111 mg/min, respectively; and the rGSARmax to GSARmax ratio values were 0.774 and 0.746±0.177, respectively. Among these, the GSARmax and rGSARmax values were significantly correlated with the liver functional parameters ICGR15, LHL15, HH15, prothrombin activity, serum hyaluronic acid level, and platelet count (all P<0.01). The rGSARmax values were significantly lower in patients with long-term ascites (P<0.05), and the predictive cutoff values of rGSARmax were 0.290 mg/min; however, the multivariate logistic regression analysis showed that rGSARmax was not independently related to long-term ascites. When accompanied by other functional liver reserve parameters, rGSARmax seemed to be an alternative liver functional parameter related to ascites.

Sections du résumé

BACKGROUND BACKGROUND
The relationship between posthepatectomy complications and liver functional parameters was preliminary reported in a pilot study. The present study sequentially evaluated the clinical significance of maximal removal rate of technetium-99m-galactosyl human serum albumin (GSARmax) in the future remnant liver (rGSARmax) in patients to predict posthepatectomy complications.
METHODS METHODS
Between 2010 and August 2017, GSARmax, rGSARmax, their difference (Dif), and the rGSARmax to GSARmax ratio were examined in 247 additional patients who underwent hepatectomy for liver and biliary diseases. Hepatectomy-related postoperative complications (i.e. long-term ascites, intra-abdominal infection, and hepatic failure) occurred in 73 (29.6%) patients.
RESULTS RESULTS
The median and mean preoperative GSARmax values were 0.477 and 0.498±0.166 mg/min, respectively; rGSARmax values were 0.341 and 0.366±0.145 mg/min, respectively; Dif values were 0.105 and 0.132±0.111 mg/min, respectively; and the rGSARmax to GSARmax ratio values were 0.774 and 0.746±0.177, respectively. Among these, the GSARmax and rGSARmax values were significantly correlated with the liver functional parameters ICGR15, LHL15, HH15, prothrombin activity, serum hyaluronic acid level, and platelet count (all P<0.01). The rGSARmax values were significantly lower in patients with long-term ascites (P<0.05), and the predictive cutoff values of rGSARmax were 0.290 mg/min; however, the multivariate logistic regression analysis showed that rGSARmax was not independently related to long-term ascites.
CONCLUSION CONCLUSIONS
When accompanied by other functional liver reserve parameters, rGSARmax seemed to be an alternative liver functional parameter related to ascites.

Identifiants

pubmed: 30650068
doi: 10.1097/MNM.0000000000000950
pii: 00006231-201902000-00008
pmc: PMC6749962
doi:

Substances chimiques

Technetium Tc 99m Aggregated Albumin 0
technetium Tc 99m DTPA-galactosyl-human serum albumin 0
Technetium Tc 99m Pentetate VW78417PU1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

145-152

Références

World J Surg. 2008 Nov;32(11):2410-8
pubmed: 18758848
Hepatology. 1997 Feb;25(2):426-9
pubmed: 9021958
Ann Surg. 1999 Mar;229(3):322-30
pubmed: 10077043
Hepatol Res. 2004 Apr;28(4):184-190
pubmed: 15040958
Am J Surg. 1992 May;163(5):515-8
pubmed: 1575310
Surg Today. 2013 May;43(5):485-93
pubmed: 23085968
Int Surg. 1980 Jul-Aug;65(4):309-13
pubmed: 7228556
Anticancer Res. 2011 Dec;31(12):4545-51
pubmed: 22199329
J Hepatobiliary Pancreat Sci. 2010 Nov;17(6):871-8
pubmed: 20734210
Hepatogastroenterology. 2010 Jan-Feb;57(97):22-8
pubmed: 20422866
Nucl Med Commun. 2017 Aug;38(8):701-707
pubmed: 28644197
Am J Surg. 1995 Jun;169(6):589-94
pubmed: 7771622
J Hepatol. 1993 Sep;19(2):232-40
pubmed: 8301056
Ann Surg. 2004 Oct;240(4):698-708; discussion 708-10
pubmed: 15383797
Br J Surg. 2012 Dec;99(12):1701-10
pubmed: 23132418
J Nucl Med. 1991 Dec;32(12):2233-40
pubmed: 1744708
World J Surg. 2002 Nov;26(11):1342-7
pubmed: 12297928
Hepatology. 2012 Dec;56(6):2221-30
pubmed: 22767263
Eur J Nucl Med. 1997 Feb;24(2):130-7
pubmed: 9021109
Surgery. 2006 Sep;140(3):379-86
pubmed: 16934599
Hepatogastroenterology. 2002 Jan-Feb;49(43):17-20
pubmed: 11941945
Scand J Clin Lab Invest. 1999 Aug;59(5):343-7
pubmed: 10533846
Ann Nucl Med. 2010 Dec;24(10):729-34
pubmed: 21061191
World J Surg. 2000 Mar;24(3):359-64
pubmed: 10658073
Eur J Nucl Med. 1998 Oct;25(10):1377-82
pubmed: 9818276

Auteurs

Yukinori Tanoue (Y)

Departments of Surgery, Division of Hepato-Biliary-Pancreas Surgery.
Department of Surgical Oncology, Nagasaki University School of Biomedical Sciences, Nagasaki, Japan.

Atsushi Nanashima (A)

Departments of Surgery, Division of Hepato-Biliary-Pancreas Surgery.

Koichi Yano (K)

Departments of Surgery, Division of Hepato-Biliary-Pancreas Surgery.

Yoshirou Fujii (Y)

Departments of Surgery, Division of Hepato-Biliary-Pancreas Surgery.

Masahide Hiyoshi (M)

Departments of Surgery, Division of Hepato-Biliary-Pancreas Surgery.

Naoya Imamura (N)

Departments of Surgery, Division of Hepato-Biliary-Pancreas Surgery.

Takeomi Hamada (T)

Departments of Surgery, Division of Hepato-Biliary-Pancreas Surgery.

Makoto Ikenoue (M)

Departments of Surgery, Division of Hepato-Biliary-Pancreas Surgery.

Takashi Wada (T)

Departments of Surgery, Division of Hepato-Biliary-Pancreas Surgery.

Yoichi Mizutani (Y)

Radiology, Faculty of Medicine, University of Miyazaki, Miyazaki.

Toshinori Hirai (T)

Radiology, Faculty of Medicine, University of Miyazaki, Miyazaki.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH